@article{JTD31352,
author = {Cheng Ji and Chongke Zhong and Shi-Yong Sun},
title = {Does osimertinib treatment discriminate young patients?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 15},
year = {2019},
keywords = {},
abstract = {Osimertinib (AZD9291 or TAGRISSO™) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) developed to overcome T790M-induced resistance, which accounts for approximately 60% of resistant cases after 1st generation EGFR-TKI treatment. Beyond T790M mutation, osimertinib also selectively and irreversibly inhibits EGFR harboring the common “sensitive” mutations such as 19del and L858R.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31352}
}